Sign in Subscribe
Cancer metastasis

ASPIRE Trial Aims to Improve Survival Rates for Advanced Prostate Cancer Patients

Strategic Insights

— 1 min read

The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial, a large-scale, Phase III clinical study investigating the effect of adding chemotherapy to current standard treatments for men with advanced prostate cancer. The trial aims to determine whether combining docetaxel, a well-established chemotherapy drug, with hormone therapy and apalutamide, a next-generation androgen receptor inhibitor, can improve overall survival for men newly diagnosed with metastatic castrate-sensitive prostate cancer. Prostate cancer is one of the most common cancers among men, with an estimated 1.5 million cases diagnosed worldwide.

Key Takeaways:

  • The ASPIRE trial is a Phase III clinical study enrolling 1,200 participants across the United States with metastatic castrate-sensitive prostate cancer (mCSPC).
  • The study will evaluate the effect of adding docetaxel to current standard treatments, including hormone therapy and apalutamide, on overall survival in men newly diagnosed with mCSPC.
  • The primary endpoint of the study is overall survival, and secondary outcomes include progression-free survival and quality of life.
  • Genomic analysis will be used to assess whether patients with mutations in TP53, PTEN, or RB1 genes benefit more from the intensified treatment.
  • The study will follow participants for up to 10 years, allowing for robust data collection on survival, disease progression, and treatment-related side effects.
  • The inclusion of genetic profiling in the ASPIRE trial reflects a growing trend toward precision oncology, where treatments are tailored to the molecular characteristics of each patient's cancer.
  • The study is supported by the National Cancer Institute (NCI) through the National Clinical Trials Network.

Statistics:

  • 1,200 participants will be enrolled in the ASPIRE trial across the United States.
  • 1.5 million cases are diagnosed with prostate cancer worldwide.
  • The study aims to improve overall survival for men with metastatic castrate-sensitive prostate cancer.
  • Patients will be monitored every six months for up to 10 years.
  • Docetaxel is a well-established chemotherapy drug used to treat various types of cancer, including prostate cancer.

Sources:

  • Alliance for Clinical Trials in Oncology
  • National Cancer Institute (NCI)
  • National Clinical Trials Network
  • NewsRx LLC (2025)

Read more